ovarian carcinoma . Cancer Surv 1989 ; 8 : 681 – 691 . 3. Longo DL Young RC . The natural history and treatment of ovarian cancer . Annu Rev Med 1981 ; 32 : 475 – 490 . 4. Hainsworth JD Grosh WW Burnett LS . Advanced ovarian
Search Results
Sumer K. Wallace, Jeff F. Lin, William A. Cliby, Gary S. Leiserowitz, Ana I. Tergas, and Robert E. Bristow
Saranya Chumsri, Jodi Weidler, Siraj Ali, Sohail Balasubramanian, Gerald Wallweber, Lisa DeFazio-Eli, Ahmed Chenna, Weidong Huang, Angela DeRidder, Lindsay Goicocheal, and Edith A. Perez
extracellular domain mutations of ERBB2 . Proc Natl Acad Sci U S A 2012 ; 109 : 14476 – 14481 . 27. Cancer Genome Atlas Research Network . Integrated genomic analyses of ovarian carcinoma . Nature 2011 ; 474 : 609 – 615 . 28
Heidi Klepin, Supriya Mohile, and Arti Hurria
hospitalized patients . JAMA 1998 ; 279 : 1187 – 1193 . 5 Freyer G Geay JF Touzet S . Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study . Ann
Julian C. Schink and Larry J. Copeland
. Clinical relevance of extent of extreme drug resistance inepithelial ovarian carcinoma . Gynecol Oncol 2010 ; 116 : 61 – 65 . 8. Cree IA Kurbacher CM Lamont A . A prospective randomized controlled trial of tumour chemosensitivity assay
Mary B. Daly, Jennifer E. Axilbund, Saundra Buys, Beth Crawford, Carolyn D. Farrell, Susan Friedman, Judy E. Garber, Salil Goorha, Stephen B. Gruber, Heather Hampel, Virginia Kaklamani, Wendy Kohlmann, Allison Kurian, Jennifer Litton, P. Kelly Marcom, Robert Nussbaum, Kenneth Offit, Tuya Pal, Boris Pasche, Robert Pilarski, Gwen Reiser, Kristen Mahoney Shannon, Jeffrey R. Smith, Elizabeth Swisher, and Jeffrey N. Weitzel
mutations. A prospective study . Gynecol Oncol 2007 ; 104 : 7 – 10 . 52. Jazaeri AA Lu K Schmandt R . Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma . Mol Carcinog 2003 ; 36 : 53 – 59 . 53
Joseph Abi Jaoude, Ramez Kouzy, Walker Mainwaring, Timothy A. Lin, Austin B. Miller, Amit Jethanandani, Andres F. Espinoza, Dario Pasalic, Vivek Verma, Noam A. VanderWalde, Benjamin D. Smith, Grace L. Smith, C. David Fuller, Prajnan Das, Bruce D. Minsky, Claus Rödel, Emmanouil Fokas, Reshma Jagsi, Charles R. Thomas Jr, Ishwaria M. Subbiah, Cullen M. Taniguchi, and Ethan B. Ludmir
second-line treatment of elderly patients with epithelial ovarian carcinoma . Cancer 2002 ; 94 : 1961 – 1967 . 10.1002/cncr.10385 11932898 2. Jang RW , Caraiscos VB , Swami N , . Simple prognostic model for patients with advanced cancer based
Megan Randall, Kelly Burgess, Lela Buckingham, and Lydia Usha
.1016/j.ygyno.2017.10.032 9. Dao F , Schlappe BA , Tseng J , . Characteristics of 10-year survivors of high-grade serous ovarian carcinoma . Gynecol Oncol 2016 ; 141 : 260 – 263 . 10.1016/j.ygyno.2016.03.010 26968641 10. Gadducci A
Kamel Izeradjene and Sunil R. Hingorani
-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination . Cancer Res 2003 ; 63 : 4441 – 4449 . 119. Curiel TJ Coukos G Zou L . Specific recruitment of regulatory T cells in ovarian carcinoma
Mary B. Daly, Robert Pilarski, Jennifer E. Axilbund, Saundra S. Buys, Beth Crawford, Susan Friedman, Judy E. Garber, Carolyn Horton, Virginia Kaklamani, Catherine Klein, Wendy Kohlmann, Allison Kurian, Jennifer Litton, Lisa Madlensky, P. Kelly Marcom, Sofia D. Merajver, Kenneth Offit, Tuya Pal, Boris Pasche, Gwen Reiser, Kristen Mahoney Shannon, Elizabeth Swisher, Nicoleta C. Voian, Jeffrey N. Weitzel, Alison Whelan, Georgia L. Wiesner, Mary A. Dwyer, and Rashmi Kumar
hamartoma-tumor syndrome . Arch Dermatol 2006 ; 142 : 625 – 632 . 28. Jazaeri AA Lu K Schmandt R . Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma . Mol Carcinog 2003 ; 36 : 53 – 59 . 29
Michaela A. Dinan, Bradford R. Hirsch, and Gary H. Lyman
epithelial ovarian carcinoma—a cost-effectiveness analysis . Int J Gynecol Cancer 2007 ; 17 : 1019 – 1024 . 38. Fust K Li X Maschio M . Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent
